The ICD-10-CM code for chemo-induced anemia is D64.81, Anemia due to antineoplastic chemotherapy. It is normally reported together with T45.1X5- (adverse effect of antineoplastic and immunosuppressive drugs) and the code for the cancer being treated. Clinically, it describes a fall in red blood cells caused by chemotherapy suppressing the bone marrow.
This article covers both halves of the topic: the coding rules that clinicians and coders need, and the medical picture behind them. For the broader coding family, see our guide to anemia ICD 10 codes.
What Is Chemo-Induced Anemia?
Chemotherapy-induced anemia is a reduction in hemoglobin or red blood cell mass that develops because of anticancer drugs. With fewer red cells, less oxygen reaches the tissues, which causes tiredness and breathlessness.
It is one of the most common side effects of cancer treatment. Red cells normally live about 120 days, so anemia often builds gradually over several chemotherapy cycles rather than appearing after the first dose.
ICD-10 Codes for Chemo-Induced Anemia
D64.81 belongs to the U.S. clinical modification (ICD-10-CM). It sits under D64, “Other anemias,” and is specific to anemia caused by chemotherapy drugs. Choosing the right code depends on what is actually causing the anemia.
| Code | Description | When to use |
|---|---|---|
| D64.81 | Anemia due to antineoplastic chemotherapy | Anemia documented as caused by chemotherapy |
| T45.1X5A / D / S | Adverse effect of antineoplastic and immunosuppressive drugs (initial, subsequent, sequela) | Paired with D64.81 to identify the drug as the cause |
| D63.0 | Anemia in neoplastic disease | Anemia caused by the cancer itself, not the treatment |
| D61.810 | Antineoplastic chemotherapy induced pancytopenia | All three cell lines low due to chemotherapy |
| D64.9 | Anemia, unspecified | Avoid when the cause is documented |
Sequencing rules
Under the ICD-10-CM official guidelines, when a patient is admitted or seen mainly to treat anemia caused by chemotherapy, and the treatment is only for the anemia, the anemia code is listed first. The neoplasm code and the T45.1X5- adverse effect code follow.
If the anemia is due to the cancer itself, D63.0 is used, and the malignancy is sequenced first. When documentation supports both causes, both D63.0 and D64.81 may be reported. The key is clear physician documentation of the cause; coders cannot assume it.
Documentation tips
- State the link explicitly, for example “anemia due to chemotherapy.”
- Name the drug or regimen and the encounter type (initial or subsequent).
- Record the hemoglobin and any treatment given, such as transfusion or ESA.
- Note other contributors, such as iron deficiency or bleeding, which carry their own codes.
Causes and Mechanisms
Most chemotherapy drugs attack rapidly dividing cells, and red cell precursors in the bone marrow divide quickly. The main cause is therefore suppressed erythropoiesis, the production of new red cells.
Other contributors include:
- Kidney effects: platinum drugs such as cisplatin can damage the kidneys, which make erythropoietin, the hormone that drives red cell production.
- Inflammation: cancer-related inflammation raises hepcidin, a hormone that locks iron away from the marrow.
- Blood loss and hemolysis: bleeding from the gut or tumor, and occasionally drug-related red cell destruction.
- Nutrition: poor appetite and nausea can lead to iron, folate, or vitamin B12 deficiency.
Risk is higher with intensive or platinum-based regimens, low hemoglobin before treatment, prior radiation to large bone areas, chronic kidney disease, and older age.
Symptoms and Grading
Symptoms reflect how low the hemoglobin is and how quickly it has fallen. Common complaints are fatigue, pale skin, shortness of breath on exertion, dizziness, rapid heartbeat, and difficulty concentrating. In people with heart disease, anemia can trigger chest pain.
Oncologists grade severity using the standard toxicity criteria:
| Grade | Hemoglobin (g/dL) | Typical meaning |
|---|---|---|
| 1 (mild) | Below normal to 10.0 | Usually monitored |
| 2 (moderate) | Below 10.0 to 8.0 | Treatment often considered |
| 3 (severe) | Below 8.0 | Transfusion frequently indicated |
| 4 | Life-threatening | Urgent intervention |
For reference, normal hemoglobin is roughly 13.5 to 17.5 g/dL in adult men and 12.0 to 15.5 g/dL in adult women.
Diagnosis
A complete blood count (CBC) measures hemoglobin, hematocrit, and the RBC count. A reticulocyte count shows whether the marrow is responding; it is typically low in chemotherapy-induced anemia.
Because chemo-induced anemia is partly a diagnosis of exclusion, clinicians also check ferritin, transferrin saturation, vitamin B12, folate, kidney function, and signs of bleeding or hemolysis. A bone marrow biopsy is reserved for unexplained or persistent cases, such as suspected marrow involvement by the cancer.
Treatment and Management
Management aims to relieve symptoms and keep treatment on schedule. The approach depends on severity, the goal of cancer treatment, and other hematological findings.
- Red blood cell transfusion: the fastest way to raise hemoglobin, used for severe or symptomatic anemia. Risks include transfusion reactions and, with repeated transfusions, iron overload.
- Erythropoiesis-stimulating agents (ESAs): drugs such as epoetin alfa and darbepoetin mimic erythropoietin. Guidelines generally reserve them for patients on chemotherapy with hemoglobin below 10 g/dL, using the lowest effective dose, because of risks including blood clots and possible effects on tumor growth.
- Iron: intravenous iron is often preferred when iron is low or unavailable to the marrow, and it can improve the response to ESAs.
- Treating other deficiencies: folate or vitamin B12 replacement when levels are low.
- Regimen adjustment: occasionally a dose delay or change, balanced against cancer control.
Most chemo-induced anemia improves over weeks to months after treatment ends as the marrow recovers. Our anemia guide covers other types that can overlap.
Key Takeaways
- ICD-10-CM D64.81 codes anemia due to antineoplastic chemotherapy, paired with T45.1X5- and the neoplasm code.
- Use D63.0 when the cancer itself causes the anemia.
- The main mechanism is marrow suppression, with kidney, inflammatory, and nutritional contributors.
- Treatment options include transfusion, ESAs, and iron, chosen by severity and treatment goals.
Frequently Asked Questions
What is the difference between D64.81 and D63.0?
D64.81 is for anemia caused by chemotherapy drugs, while D63.0 is for anemia caused by the cancer itself. If documentation supports both causes, both codes can be reported.
Does D64.81 need an additional code?
Yes. Coders add T45.1X5- with the correct seventh character to identify the drug as the cause, along with the code for the underlying malignancy.
How long does chemo-induced anemia last?
It usually improves within weeks to a few months after the last cycle as the marrow recovers. Recovery can be slower after very intensive treatment or in people with kidney problems.
Can diet fix anemia caused by chemotherapy?
A balanced diet helps, especially if iron, folate, or B12 is low, but it cannot overcome marrow suppression. Significant anemia usually needs medical treatment.
